These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 17613409)

  • 1. Recurrent treatment of refractory acute cellular rejection with alemtuzumab after lung transplantation.
    van Haren E; van Vugt LK; Wijbenga N; van der Sijs H; Hellemons ME
    J Heart Lung Transplant; 2024 Jul; ():. PubMed ID: 39009290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Center Volume Is a Relatively Small Contributor to Outcomes After Heart Transplant.
    Choi K; Schumer EM
    ASAIO J; 2023 Sep; 69(9):871-872. PubMed ID: 37579003
    [No Abstract]   [Full Text] [Related]  

  • 3. De Novo Donor-Specific Antibodies after Heart Transplantation: A Comprehensive Guide for Clinicians.
    Marco I; López-Azor García JC; González Martín J; Severo Sánchez A; García-Cosío Carmena MD; Mancebo Sierra E; de Juan Bagudá J; Castrodeza Calvo J; Hernández Pérez FJ; Delgado JF
    J Clin Med; 2023 Dec; 12(23):. PubMed ID: 38068526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating donor-derived cell-free DNA: a true biomarker for cardiac allograft rejection?
    Daly KP
    Ann Transl Med; 2015 Mar; 3(4):47. PubMed ID: 25861602
    [No Abstract]   [Full Text] [Related]  

  • 5. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant.
    Waggoner J; Martinu T; Palmer SM
    J Heart Lung Transplant; 2009 Apr; 28(4):395-8. PubMed ID: 19332268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use.
    Das B; Shoemaker L; Recto M; Austin E; Dowling R
    J Heart Lung Transplant; 2008 Feb; 27(2):242-4. PubMed ID: 18267235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
    Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection.
    Woodside KJ; Lick SD
    J Heart Lung Transplant; 2007 Jul; 26(7):750-2. PubMed ID: 17613409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.
    Magliocca JF; Knechtle SJ
    Transpl Int; 2006 Sep; 19(9):705-14. PubMed ID: 16918530
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.